© 2022 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Recommendations for treating HER2-positive metastatic breast cancer with newer HER2-targeted treatment approaches and considerations regarding their adoption into clinical practice.
June 15th 2021
Frontline therapies available for newly diagnosed HER2-positive metastatic breast cancer and variables that impact treatment selection.
Ian E. Krop, MD, PhD, of Dana-Faber Cancer Institute, highlights more recent targeted therapy approvals for HER2-positive metastatic breast cancer and describes how each therapy is designed to work.
June 22nd 2021
Considerations regarding how to best integrate newer targeted therapies available for HER2-positive metastatic breast cancer [MBC] into clinical practice.
Ian E Krop, MD, PhD, elaborates on which treatment settings are most appropriate to use HER2-targeted therapies in to manage metastatic breast cancer.
June 29th 2021
The rationale for treating metastatic breast cancer with a dual HER2-targeted therapy approach.
The impact of the COVID-19 pandemic on the utilization of newer targeted therapies for HER2-positive metastatic breast cancer and considerations regarding their adoption into clinical practice based on the availability of vaccines.
July 21st 2021
Debra Patt, MD, PhD, MBA, describes the frontline standards of care and the factors involved in deciding on a treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer.
An expert in HER2-positive metastatic breast cancer discusses the new targeted treatment regimens for patients.
July 28th 2021
Debra Patt, MD, PhD, MBA, discusses the cost considerations of conventional and novel therapies for HER2-positive metastatic breast cancer.
Debra Patt, MD, PhD, MBA, explains how clinical practice has adapted to the use of targeted therapies to treat HER2-positive metastatic breast cancer.